Significant Ownership of Opaleye Management Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Opaleye Management Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ James Silverman - President
- Manager location
- Boston, MA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Opaleye Management Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Opaleye Management Inc.
Significant Ownership of Opaleye Management Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd | Ordinary Shares, par value NIS 1.00 per share. | 15% | $37,430,000 | +$2,969,322 | 500,000 | +8.6% | Opaleye Management Inc. | 31 Mar 2026 |
| ACOG | Alpha Cognition Inc. | Common Stock, no par value | 14% | $20,675,889 | +$1,336,574 | 3,095,193 | +6.9% | Opaleye Management Inc. | 23 Jul 2026 |
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, no par value | 9.5% | $10,262,842 | 1,569,002 | Opaleye Management Inc. | 10 Oct 2025 | ||
| IBIO | iBio, Inc. | Common Stock, par value $0.001 per share | 7.6% | $787,500 | 750,000 | Opaleye Management, Inc. | 31 Dec 2024 | ||
| CDXS | Codexis, Inc. | Common Stock, par value $0.0001 per share | 7.5% | $16,284,000 | -$11,371 | 6,785,000 | -0.07% | Opaleye Management Inc. | 31 Mar 2026 |
| RZLT | Rezolute, Inc. | Common Stock | 6.6% | $22,932,000 | +$5,049,044 | 6,300,000 | +28% | Opaleye Management Inc. | 31 Mar 2026 |
| HROW | Harrow, Inc. | Common Stock, $0.001 par value per share | 6.4% | $108,168,000 | -$19,480,606 | 2,400,000 | -15% | Opaleye Management Inc. | 30 Jun 2026 |
| KTTA | Pasithea Therapeutics Corp. | Common Stock, par value $0.0001 per share | 6.1% | $1,004,500 | -$216,090 | 2,050,000 | -18% | Opaleye Management Inc. | 30 Jun 2026 |
| QTTB | Q32 Bio Inc. | Common Stock, par value $0.0001 per share | 5.5% | $19,904,780 | -$6,953,375 | 931,000 | -26% | Opaleye Management Inc. | 30 Jun 2026 |
| GOSS | Gossamer Bio, Inc. | Common Stock, par value $0.0001 per share | 5.1% | $4,105,546 | 24,942,565 | Opaleye Management Inc. | 22 Jul 2026 | ||
| LRMR | Larimar Therapeutics, Inc. | Common Stock | 4.8% | $15,412,500 | +$590,966 | 4,110,000 | +4% | Opaleye Management, Inc. | 29 Aug 2025 |
| TARA | Protara Therapeutics, Inc. | Common Stock | 4.7% | $7,473,600 | -$410,400 | 1,730,000 | -5.2% | Opaleye Management, Inc. | 31 Mar 2025 |
| SNWV | SANUWAVE Health, Inc. | Common Stock, par value $0.001 per share | 3.6% | $3,620,193 | -$6,407,893 | 309,948 | -64% | Opaleye Management Inc. | 30 Jun 2026 |
| OCUL | OCULAR THERAPEUTIX, INC | Common Stock, par value $0.0001 per share | 2.8% | $34,305,750 | 4,342,500 | Opaleye Management Inc. | 31 Dec 2024 | ||
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 2.7% | $371,453 | 619,089 | Opaleye Management Inc. | 31 Mar 2026 | ||
| CNTX | Context Therapeutics Inc. | Common Stock, par value $0.001 per share | 0% | $0 | 0 | Opaleye Management Inc. | 31 Dec 2024 |
Schedules 13D/G Reported by Opaleye Management Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.